Guardian Pharmacy Services, Inc. (GRDN) Stock Price & Analysis
Guardian Pharmacy Services, Inc. (GRDN) — MoonshotScore 96/100 (Exceptional band), calculated Nov 18, 2026. Price $46.94 (+0.58%), as of the Nov 20, 2026 trading session; market cap $2.97B.
Educational signal · not a buy or sell recommendation · How to read this
Guardian Pharmacy Services, Inc. · GRDN · NYSE
Guardian Pharmacy Services, Inc. provides technology-enabled pharmacy services to residents in long-term health care facilities (LTCFs) in the United States, focusing on lower acuity facilities. They offer individualized clinical, drug dispensing, and administration capabilities, supported by data-driven insights.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Guardian Pharmacy Services (GRDN)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but a full valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Full; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- Altman Z 13.15 · Piotroski F 6
- ROE 32.0% · ROA 13.4% · current ratio 1.65
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 97 | Exceptional | |
| 97 | Exceptional | |
| 97 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional | |
| 96 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $46.94 | |
| Change on the day | +0.58% | |
| 52-week range | $26.34 – $50.59 | |
| Market capitalisation | $2.97B | — |
| Price / earnings (trailing) | 42.65 | |
| Shares traded on the day | 526.7K |
Price & events
Other perspectives
Council score for Guardian Pharmacy Services (GRDN): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 20, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company less favourably than the MoonshotScore does: Griffin-style lens and Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Guardian Pharmacy Services (GRDN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Guardian Pharmacy Services, Inc. (GRDN) is listed on NYSE. It employs 3,600 people and is led by Fred Burke. The market values it at $2.97B.
What do the latest results show for Guardian Pharmacy Services (GRDN)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $377M | $10M | $0.15 (diluted) |
| Q4 FY2025 | $398M | $21M | $0.33 (diluted) |
| Q1 FY2026 | $337M | $13M | $0.21 (diluted) |
| Q2 FY2026 | $352M | $22M | $0.34 (diluted) |
What are the financial strengths and risks for Guardian Pharmacy Services (GRDN)?
Short answer
The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 13.15 · Piotroski F 6. Trailing ratios: ROE 32.0% · ROA 13.4% · current ratio 1.65.
What should you watch next at Guardian Pharmacy Services (GRDN)?
Short answer · as of
The stored analyst-target capture is expired, so a current target watchpoint is unavailable.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Guardian Pharmacy Services compare with its peers?
Short answer
Guardian Pharmacy Services's score ranks 1st of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| Guardian Pharmacy Services (GRDN) — this page | $46.94 | $2.97B | 96 |
| $121.07 Nov 19, 2026 | $2.26B | 93 5-pillar Nov 18, 2026 | |
| $24.77 Nov 19, 2026 | $1.67B | 93 5-pillar Nov 18, 2026 | |
| $13.34 Nov 19, 2026 | $5.07B | 92 5-pillar Nov 18, 2026 | |
| $31.61 Nov 19, 2026 | $4.74B | 85 5-pillar Nov 18, 2026 | |
| $41.17 Nov 19, 2026 | $4.51B | 84 5-pillar Nov 18, 2026 | |
| $29.94 Nov 19, 2026 | $2.34B | 82 5-pillar Nov 18, 2026 | |
| $14.50 Nov 19, 2026 | $2.04B | 81 5-pillar Nov 18, 2026 | |
| $188.55 Nov 19, 2026 | $2.95B | 76 5-pillar Nov 18, 2026 | |
| $10.70 Nov 19, 2026 | $2.34B | 75 5-pillar Nov 18, 2026 | |
| $16.01 Nov 20, 2026 | $4.50B | 38 5-pillar Nov 18, 2026 | |
| $89.50 Nov 19, 2026 | $1.50B | 36 5-pillar Nov 18, 2026 | |
| $26.69 Nov 19, 2026 | $3.49B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Last captured analyst target range, low to high (expired, captured Nov 18, 2026)
- $49.00 – $52.00
- Last captured analyst target (expired, captured Nov 18, 2026)
- $50.67
- Last captured median analyst target (expired, captured Nov 18, 2026)
- $51.00
Historical target record · Captured · Capture expired; not a current watchpoint.
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Sep 27, 2026
- Transactions
- 33
- Identified insiders
- 16
- Purchases
- 0
- Sales
- 0
- Other transactions
- 33
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held GRDN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported GRDN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Guardian Pharmacy Services (GRDN)?
What Investors Ask About Guardian Pharmacy Services (GRDN)
These answers are editorial: 1 of these 9 answers is drawn from the GRDN research dossier (written May 6, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for GRDN?
GRDN carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is GRDN a good stock to buy?
Stock Expert AI does not rate GRDN buy, sell or hold. Guardian Pharmacy Services, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the GRDN stock price today?
The last price recorded for Guardian Pharmacy Services, Inc. (GRDN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the GRDN price target?
The last analyst consensus price target we captured for Guardian Pharmacy Services, Inc. (GRDN), with its FMP capture date, is listed under Analyst targets & estimates on this page. That capture has expired, so read it as historical, not as a current target. Targets are analyst opinions, not a Stock Expert AI forecast.
What does Guardian Pharmacy Services, Inc. do?
Guardian Pharmacy Services, Inc. provides technology-enabled pharmacy services to residents in long-term health care facilities (LTCFs) across the United States.
What are the key factors to evaluate for GRDN?
Guardian Pharmacy Services, Inc. (GRDN) holds a MoonshotScore in the high range. To weigh it, start with the trailing P/E under Price & valuation on this page. By aligning its interests with those of LTCF providers, Guardian can strengthen its customer relationships and drive long-term growth. Not financial advice.
How frequently does GRDN data refresh on this page?
GRDN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven GRDN's recent stock price performance?
Guardian Pharmacy Services, Inc. (GRDN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized expertise in serving lower acuity LTCFs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider GRDN overvalued or undervalued right now?
The trailing P/E of Guardian Pharmacy Services, Inc. (GRDN) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 6, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com